Calypte Supports State of the Union Address HIV/AIDS Initiative
LAKE OSWEGO, Ore., Jan. 25 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market today announced its continued support for President George W. Bush's efforts to prevent, treat and ultimately defeat HIV/AIDS, as stated in his recent State of the Union address. In that address, President Bush asked Congress to commit $15 billion over the next five years, including nearly $10 billion in new money, to turn the tide against AIDS in the most afflicted nations of Africa and the Caribbean.
According to the December 2006 AIDS Epidemic Update, published jointly by the Joint United Nations Programme on HIV/AIDS ("UNAIDS") and the World Health Organization, Sub-Saharan Africa has just over 10% of the world's population, but is home to almost two thirds (63%) of all people living with HIV-some 24.7 million. In 2006, an estimated 2.8 million people in the region became newly infected, while 2.1 million adults and children died of AIDS, representing 72% of global AIDS deaths.
Calypte has received regulatory approvals and is actively marketing its Aware(TM) line of HIV-1/2 rapid tests in Kenya, Malaysia, Russia, South Africa, UAE, Uganda and Zimbabwe. Calypte has also recently received USAID approval for its Aware(TM) HIV-1/2 BSP test and is currently pursuing USAID approval for its Aware(TM) HIV-1/2 OMT test. The USAID approval qualifies the tests for use in PEPFAR funded programs. During the second half of 2006 Calypte received orders for distribution of its Aware(TM) HIV-1/2 oral fluid rapid test in the United Arab Emirates (UAE), Russia and Africa.
Roger Gale, Calypte's Chairman and Chief Executive Officer commented, "Calypte is proud to be participating in the war against HIV/AIDS in such a meaningful and timely way. Our Aware(TM) HIV-1/2 oral fluid rapid tests are safer, more appealing to patients and generally more cost effective than blood rapid tests. They are especially well suited for use in rural outreach settings. We look forward to keeping our product in the locations that are so devastated by this disease."
Mijns inziens weinig nieuwswaarde. Lijkt een beetje op een poging om duidelijk te maken dat ze nog bestaan....Zal wel (weer) geen invloed hebben op koers, zoals ook eerdere (meer inhoudelijke) persberichten dat niet hadden...
Maar weer een jaartje afwachten en hopen dat ze niet failliet gaan.